Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Financial Officer

Chief Legal Officer, Corp. Sec

Chief Medical Officer

SVP of R&D

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-02-21	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-02-13	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-02-06	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-01-30	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-01-23	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-01-17	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-12-16	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-12-16	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-12-09	Premium	bought	Premium	Premium	Premium	Chief Legal Officer, Corp. Sec
2022-08-19	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-08-17	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-08-16	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2021-12-16	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-10-22	Premium	bought	Premium	Premium	Premium	Chief Legal Officer, Corp. Sec
2021-10-22	Premium	acquired	Premium	Premium	Premium	SVP of R&D
2021-10-22	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-10-22	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2021-10-22	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-10-22	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer

CNTX - Context Therapeutics Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for CNTX